Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Opportunities for the Development of Newer Drugs for Ocular Use

  • Chapter
  • First Online:
Pharmacology of Ocular Therapeutics

  • 1581 Accesses

Abstract

Both anatomically and physiologically, eye is a unique organ containing several widely varied structures with independent physiological functions. Eye has a number of distinct features in contrast to other organs as it is isolated from systemic access by the blood-retinal, blood-aqueous, and blood-vitreous barriers. Topically administered drugs as instillations on eye face a hydrodynamic surface wherein the physio-chemical properties of the drug determine its penetration across the cornea. Therefore, drug development for eye requires extensive developmental considerations to overcome these barriers. This chapter reveals the novel targets for ocular drug research in the areas of neovascularization, glaucoma, AMD, pharmacological vitreolysis, genomic studies and drug delivery.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Adamis AP, Miller JW, Bernal MT, D’Amico DJ, Folkman J, Yeo TK, Yeo KT. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol. 1994;118(4):445–50.

    Article  PubMed  CAS  Google Scholar 

  • Adelman R, Parnes A, Michalewska Z, Parolini B, Boscher C, Ducournau D. Strategy for the management of diabetic macular edema: the European vitreo-retinal society macular edema study. Biomed Res Int. 2015;2015:352487.

    Google Scholar 

  • Akpek EK, Smith RA. Overview of age-related ocular conditions. Am J Manag Care. 2013;19(5 Suppl):S67–75.

    PubMed  Google Scholar 

  • Alon T, Hemo I, Itin A, Pe’er J, Stone J, Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med. 1995;1:1024–8.

    Article  PubMed  CAS  Google Scholar 

  • Alward WL. Biomedicine. A new angle on ocular development. Science. 2003;299:1527–8.

    Article  PubMed  CAS  Google Scholar 

  • Arthur S, Cantor LB. Update on the role of alpha-agonists in glaucoma management. Exp Eye Res. 2011;93(3):271–83.

    Article  PubMed  CAS  Google Scholar 

  • Bandello F, La Spina C, Iuliano L, Fogliato G, Parodi MB. Review and perspectives on pharmacological vitreolysis. Ophthalmologica. 2013;230(4):179–85.

    Article  PubMed  CAS  Google Scholar 

  • Baramova EN, Bajou K, Remacle A, L’Hoir C, Krell HW, Weidle UH, Noel A, Foidart JM. Involvement of PA/plasmin system in the processing of pro-MMP-9 and in the second step of pro-MMP-2 activation. FEBS Lett. 1997;405:157–62.

    Article  PubMed  CAS  Google Scholar 

  • Berni R, Formelli F. In vitro interaction of fenretinide with plasma retinol-binding protein and its functional consequences. FEBS Lett. 1992;308:43–5.

    Article  PubMed  CAS  Google Scholar 

  • Bock F, König Y, Dietrich T, Zimmermann P, Baier M, Cursiefen C. Inhibition of angiogenesis in the anterior chamber of the eye. Ophthalmologe. 2007;104:336–44.

    Article  PubMed  CAS  Google Scholar 

  • Chen TC. Brimonidine 0.15% versus apraclonidine 0.5% for prevention of intraocular pressure elevation after anterior segment laser surgery. J Cataract Refract Surg. 2005;31(9):1707–12.

    Article  PubMed  Google Scholar 

  • Chen R, Li GL. Neuroprotection of retinal degenerative disease by ciliary neurotrophic factor. Zhonghua Yan Ke Za Zhi. 2011;47(6):568–72.

    PubMed  CAS  Google Scholar 

  • Cleveland RP, Hazlett LD, Leon MA, Berk RS. Role of complement in murine corneal infection caused by Pseudomonas aeruginosa. Invest Ophthalmol Vis Sci. 1983;24(2):237–42.

    PubMed  CAS  Google Scholar 

  • Collier RJ, Patel Y, Martin EA, Dembinska O, Hellberg M, Krueger DS, Kapin MA, Romano C. Agonists at the serotonin receptor (5-HT(1A)) protect the retina from severe photo-oxidative stress. Invest Ophthalmol Vis Sci. 2011;52(5):2118–26.

    Article  PubMed  CAS  Google Scholar 

  • Cooke Bailey JN, Sobrin L, Pericak-Vance MA, Haines JL, Hammond CJ, Wiggs JL. Advances in the genomics of common eye diseases. Hum Mol Genet. 2013;22(R1):R59–65.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Cunha-Vaz J, Ashton P, Iezzi R, Campochiaro P, Dugel PU, Holz FG, Weber M, Danis RP, Kuppermann BD, Bailey C, Billman K, Kapik B, Kane F, Green K, FAME Study Group. Sustained delivery fluocinolone acetonide vitreous implants: long-term benefit in patients with chronic diabetic macular edema. Ophthalmology. 2014;121(10):1892–903.

    Article  PubMed  Google Scholar 

  • Daka Q, Trkulja V. Efficacy and tolerability of mono-compound topical treatments for reduction of intraocular pressure in patients with primary open angle glaucoma or ocular hypertension: an overview of reviews. Croat Med J. 2014;55(5):468–80.

    Article  PubMed Central  PubMed  Google Scholar 

  • El Sayed KA, Youssef DT, Marchetti D. Bioactive natural and semisynthetic latrunculins. J Nat Prod. 2006;69(2):219–23.

    Article  PubMed  CAS  Google Scholar 

  • Eveleth DD. Cell-based therapies for ocular disease. J Ocul Pharmacol Ther. 2013;29(10):844–54.

    Article  PubMed  CAS  Google Scholar 

  • Fan S, Agrawal A, Gulati V, Neely DG, Toris CB. Daytime and nighttime effects of brimonidine on IOP and aqueous humor dynamics in participants with ocular hypertension. J Glaucoma. 2014;23(5):276–81.

    Article  PubMed Central  PubMed  Google Scholar 

  • Friedman DS, O’Colmain BJ, Muñoz B, Tomany SC, McCarty C, de Jong PT, Nemesure B, Mitchell P, Kempen J. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122:564–72.

    Article  PubMed  Google Scholar 

  • Gerl VB, Bohl J, Pitz S, Stoffelns B, Pfeiffer N, Bhakdi S. Extensive deposits of complement C3d and C5b-9 in the choriocapillaris of eyes of patients with diabetic retinopathy. Invest Ophthalmol Vis Sci. 2002;43(4):1104–8.

    PubMed  Google Scholar 

  • Gillies MC, Lim LL, Campain A, Quin GJ, Salem W, Li J, Goodwin S, Aroney C, McAllister IL, Fraser-Bell S. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology. 2014;121(12):2473–81.

    Article  PubMed  Google Scholar 

  • Goldberg MA, Schneider TJ. Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin. J Biol Chem. 1994;269:4355–9.

    PubMed  CAS  Google Scholar 

  • Good TJ, Kahook MY. The role of endothelin in the pathophysiology of glaucoma. Expert Opin Ther Targets. 2010;14(6):647–54.

    Article  PubMed  CAS  Google Scholar 

  • Hageman GS, Anderson DH, Johnson LV, Hancox LS, et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S A. 2005;102(20):7227–32.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Heier JS, Antoszyk AN, Pavan PR, Leff SR, Rosenfeld PJ, Ciulla TA, Dreyer RF, Gentile RC, Sy JP, Hantsbarger G, Shams N. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology. 2006;113(4):633.e1–4.

    Article  Google Scholar 

  • Inoue K, Shiokawa M, Sugahara M, Wakakura M, Soeda S, Tomita G. Three-month evaluation of dorzolamide hydrochloride/timolol maleate fixed-combination eye drops versus the separate use of both drugs. Jpn J Ophthalmol. 2012;56(6):559–63.

    Article  PubMed  CAS  Google Scholar 

  • Jacot JL, Sherris D. Potential therapeutic roles for inhibition of the PI3K/Akt/mTOR pathway in the pathophysiology of diabetic retinopathy. J Ophthalmol. 2011;2011:589813.

    Google Scholar 

  • Jha P, Bora PS, Bora NS. The role of complement system in ocular diseases including uveitis and macular degeneration. Mol Immunol. 2007;44(16):3901–8.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Joachim ND, Mitchell P, Kifley A, Wang JJ. Incidence, Progression, and Associated Risk Factors of Medium Drusen in Age-Related Macular Degeneration: Findings from the 15-Year Follow-up of an Australian Cohort. JAMA Ophthalmol. 2015;133(6):698–705.

    Google Scholar 

  • Johnson LV, Forest DL, Banna CD, Radeke CM, Maloney MA, Hu J, Spencer CN, Walker AM, Tsie MS, Bok D, Radeke MJ, Anderson DH. Cell culture model that mimics drusen formation and triggers complement activation associated with age-related macular degeneration. Proc Natl Acad Sci U S A. 2011;108(45):18277–82.

    Article  PubMed Central  PubMed  Google Scholar 

  • Józsi M, Zipfel PF. Factor H family proteins and human diseases. Trends Immunol. 2008;29(8):380–7.

    Article  PubMed  CAS  Google Scholar 

  • Kalita D, Shome D, Jain VG, Chadha K, Bellare JR. In vivo intraocular distribution and safety of periocular nanoparticle carboplatin for treatment of advanced retinoblastoma in humans. Am J Ophthalmol. 2014;157(5):1109–15.

    Article  PubMed  CAS  Google Scholar 

  • Kambhampati SP, Mishra MK, Mastorakos P, Oh Y, Lutty GA, Kannan RM. Intracellular delivery of dendrimer triamcinolone acetonide conjugates into microglial and human retinal pigment epithelial cells. Eur J Pharm Biopharm. 2015;pii: S0939 –6411(15):00095–8.

    Google Scholar 

  • Kastelan S, Zjacić-Rotkvić V, Kastelan Z. Could diabetic retinopathy be an autoimmune disease? Med Hypotheses. 2007;68(5):1016–8.

    Article  PubMed  CAS  Google Scholar 

  • Kawashima Y, Oishi A, Tsujikawa A, Yamashiro K, Miyake M, Ueda-Arakawa N, Yoshikawa M, Takahashi A, Yoshimura N. Effects of aflibercept for ranibizumab-resistant neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol. 2015;253(9):1471–7.

    Google Scholar 

  • Khandhadia S, Hakobyan S, Heng LZ, et al. Age-related macular degeneration and modification of systemic complement factor H production through liver transplantation. Ophthalmology. 2013;120(8):1612–8.

    Article  PubMed  Google Scholar 

  • Khoshnevis M1, Sebag J. Pharmacologic vitreolysis with ocriplasmin: rationale for use and therapeutic potential in vitreo-retinal disorders. BioDrugs. 2015;29(2):103–12.

    Google Scholar 

  • Kim JH, Lee NY, Jung SW, Park CK. Expression of N-methyl-d-aspartate receptor 1 in rats with chronic ocular hypertension. Neuroscience. 2007;149(4):908–16.

    Article  PubMed  CAS  Google Scholar 

  • Kniep EM, Roehlecke C, Ozkucur N, Steinberg A, Reber F, Knels L, Funk RH. Inhibition of apoptosis and reduction of intracellular PH decrease in retinal neural cell cultures by a blocker of carbonic anhydrase. Invest Ophthalmol Vis Sci. 2006;47(3):1185–11892.

    Article  PubMed  Google Scholar 

  • Kubota R, Boman NL, David R, Mallikaarjun S, Patil S, Birch D. Safety and effect on rod function of ACU-4429, a novel small-molecule visual cycle modulator. Retina. 2012;32(1):183–8.

    Article  PubMed  Google Scholar 

  • Lindén C, Alm A. Prostaglandin analogues in the treatment of glaucoma. Drugs Aging. 1999;14(5):387–98.

    Article  PubMed  Google Scholar 

  • Lindsey JD, Duong-Polk KX, Hammond D, Chindasub P, Leung CK, Weinreb RN. Differential protection of injured retinal ganglion cell dendrites by brimonidine. Invest Ophthalmol Vis Sci. 2015;56(3):1789–804.

    Article  PubMed  Google Scholar 

  • Liotta LA, Goldfarb RH, Brundage R, Siegal GP, Terranova V, Garbisa S. Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res. 1981;41:4629–36.

    PubMed  CAS  Google Scholar 

  • Liu JHK, Weinreb RN. Monitoring intraocular pressure for 24 h. Br J Ophthalmol. 2011;95(5):599–600.

    Article  PubMed  Google Scholar 

  • Maines LW, French KJ, Wolpert EB, Antonetti DA, Smith CD. Pharmacologic manipulation of sphingosine kinase in retinal endothelial cells: implications for angiogenic ocular diseases. Invest Ophthalmol Vis Sci. 2006;47(11):5022–31.

    Article  PubMed Central  PubMed  Google Scholar 

  • Margherio AR, Margherio RR, Hartzer M, Trese MT, Williams GA, Ferrone PJ. Plasmin enzyme-assisted vitrectomy in traumatic pediatric macular holes. Ophthalmology. 1998;105:1617–20.

    Article  PubMed  CAS  Google Scholar 

  • Martinez-Zapata MJ, Martí-Carvajal AJ, Solà I, Pijoán JI, Buil-Calvo JA, Cordero JA, Evans JR. Anti-vascular endothelial growth factor for proliferative diabetic retinopathy. Cochrane Database Syst Rev. 2014;11:D008721.

    Google Scholar 

  • Mata NL, Weng J, Travis GH. Biosynthesis of a major lipofuscin fluorophore in mice and humans with ABCR-mediated retinal and macular degeneration. Proc Natl Acad Sci U S A. 2000;97:7154–9.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Mata NL, Lichter JB, Vogel R, Han Y, Bui TV, Singerman LJ. Investigation of oral fenretinide for treatment of geographic atrophy in age-related macular degeneration. Retina. 2013;33(3):498–507.

    Article  PubMed  CAS  Google Scholar 

  • Michalewski J, Nawrocki J, TrÄ™biÅ„ska M, Michalewska Z. Switch to a single dose of aflibercept in bevacizumab nonresponders with AMD. Can J Ophthalmol. 2014;49(5):431–5.

    Article  PubMed  Google Scholar 

  • Migdal C. Glaucoma medical treatment: philosophy, principles and practice. Eye (Lond). 2000;14:515–8.

    Article  Google Scholar 

  • Moiseyev G, Nikolaeva O, Chen Y, Farjo K, Takahashi Y, Ma JX. Inhibition of the visual cycle by A2E through direct interaction with RPE65 and implications in Stargardt disease. Proc Natl Acad Sci U S A. 2010;107(41):17551–6.

    Article  PubMed Central  PubMed  Google Scholar 

  • Mondino BJ, Glovsky MM, Ghekiere L. Activated complement in inflamed aqueous humor. Invest Ophthalmol Vis Sci. 1984;25(7):871–3.

    PubMed  CAS  Google Scholar 

  • Mondino BJ, Chou HJ, Sumner HL. Generation of complement membrane attack complex in normal human corneas. Invest Ophthalmol Vis Sci. 1996;37(8):1576–81.

    PubMed  CAS  Google Scholar 

  • Morrison DG, Aschner M. Vascular endothelial growth factor response to insulin-like growth factor in normoxic and hypoxic cell culture. Invest Ophthalmol Vis Sci. 2007;48:E-Abstract 1735.

    Google Scholar 

  • Morrison PW, Khutoryanskiy VV. Advances in ophthalmic drug delivery. Ther Deliv. 2014;5(12):1297–315.

    Article  PubMed  CAS  Google Scholar 

  • Moshfeghi AA, Rosenfeld PJ, Puliafito CA, Michels S, Marcus EN, Lenchus JD, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology. 2006;113(11):2002.e1–12.

    Article  Google Scholar 

  • Nathanson JA. Human ciliary process adrenergic receptor: pharmacological characterization. Invest Ophthalmol Vis Sci. 1981;21:798–804.

    PubMed  CAS  Google Scholar 

  • Pease ME, Zack DJ, Berlinicke C, Bloom K, Cone F, Wang Y, Klein RL, Hauswirth WW, Quigley HA. Effect of CNTF on retinal ganglion cell survival in experimental glaucoma. Invest Ophthalmol Vis Sci. 2009;50(5):2194–200.

    Article  PubMed Central  PubMed  Google Scholar 

  • Peden MC, Suñer IJ, Hammer ME, Grizzard WS. Long-term outcomes in eyes receiving fixed-interval dosing of anti-vascular endothelial growth factor agents for wet age-related macular degeneration. Ophthalmology. 2015;122(4):803–8.

    Article  PubMed  Google Scholar 

  • Pe’er J, Shweiki D, Itin A, Hemo I, Gnessin H, Keshet E. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest. 1995;72(6):638–45.

    PubMed  Google Scholar 

  • Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, Hartnett ME. Vascular endothelial growth factor in eye disease. Prog Retin Eye Res. 2008;27(4):331–71.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Pierce EA, Foley ED, Smith LE. Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch Ophthalmol. 1996;114(10):1219–28.

    Article  PubMed  CAS  Google Scholar 

  • Pinard MA, Boone CD, Rife BD, Supuran CT, McKenna R. Structural study of interaction between brinzolamide and dorzolamide inhibition of human carbonic anhydrases. Bioorg Med Chem. 2013;21(22):7210–5.

    Article  PubMed  CAS  Google Scholar 

  • Provis JM, Leech J, Diaz CM, Penfold PL, Stone J, Keshet E. Development of the human retinal vasculature: cellular relations and VEGF expression. Exp Eye Res. 1997;65:555–68.

    Article  PubMed  CAS  Google Scholar 

  • Rasmussen CA, Kaufman PL, Ritch R, Haque R, Brazzell RK, Vittitow JL. Latrunculin B Reduces Intraocular Pressure in Human Ocular Hypertension and Primary Open-Angle Glaucoma. Transl Vis Sci Technol. 2014;3(5):1.

    Article  PubMed Central  PubMed  Google Scholar 

  • Rein DB, Zhang P, Wirth KE, Lee PP, Hoerger TJ, McCall N, Klein R, Tielsch JM, Vijan S, Saaddine J. The economic burden of major adult visual disorders in the United States. Arch Ophthalmol. 2006;124:1754–60.

    Article  PubMed  Google Scholar 

  • Resch H, Karl K, Weigert G, Wolzt M, Hommer A, Schmetterer L, Garhöfer G. Effect of dual endothelin receptor blockade on ocular blood flow in patients with glaucoma and healthy subjects. Invest Ophthalmol Vis Sci. 2009;50(1):358–63.

    Article  PubMed  Google Scholar 

  • Resnikoff S, Pascolini D, Etya’ale D, Kocur I, Pararajasegaram R, Pokharel GP, Mariotti SP. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004;82:844–51.

    PubMed Central  PubMed  Google Scholar 

  • Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005;36:331–5.

    PubMed  Google Scholar 

  • Samuel W1, Kutty RK, Duncan T, Vijayasarathy C, Kuo BC, Chapa KM, Redmond TM. Fenretinide induces ubiquitin-dependent proteasomal degradation of stearoyl-CoA desaturase in human retinal pigment epithelial cells. J Cell Physiol. 2014;229(8):1028–38.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Sasore T, Reynolds AL, Kennedy BN. Targeting the PI3K/Akt/mTOR pathway in ocular neovascularization. Adv Exp Med Biol. 2014;801:805–11.

    Article  PubMed  Google Scholar 

  • Schachar RA, Raber S, Courtney R, Zhang M. A phase 2, randomized, dose–response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension. Curr Eye Res. 2011;36(9):809–17.

    Article  PubMed  CAS  Google Scholar 

  • Schmidt KG, Bergert H, Funk RH. Neurodegenerative diseases of the retina and potential for protection and recovery. Curr Neuropharmacol. 2008;6(2):164–78.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Schmidt-Erfurth U, Chong V, Loewenstein A, Larsen M, Souied E, Schlingemann R, Eldem B, Monés J, Richard G, Bandello F, European Society of Retina Specialists. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol. 2014;98(9):1144–67.

    Article  PubMed Central  PubMed  Google Scholar 

  • Schmucker C, Ehlken C, Agostini HT, Antes G, Ruecker G, Lelgemann M, Loke YK. A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus gold standard. PLoS One. 2012;7(8):e42701.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Scozzafava A, Supuran CT. Glaucoma and the applications of carbonic anhydrase inhibitors. Subcell Biochem. 2014;75:349–59.

    Article  PubMed  CAS  Google Scholar 

  • Sebag J. Pharmacologic vitreolysis. Retina. 1998;18(1):1–3.

    Article  PubMed  CAS  Google Scholar 

  • Sena DF, Lindsley K. Neuroprotection for treatment of glaucoma in adults. Cochrane Database Syst Rev. 2013;2, CD006539.

    PubMed Central  PubMed  Google Scholar 

  • Shams N, Ianchulev T. Role of vascular endothelial growth factor in ocular angiogenesis. Ophthalmol Clin North Am. 2006;19(3):335–44.

    PubMed  Google Scholar 

  • Sivaprasad S, Adewoyin T, Bailey TA, Dandekar SS, Jenkins S, Webster AR, Chong NV. Estimation of systemic complement C3 activity in age-related macular degeneration. Arch Ophthalmol. 2007;125(4):515–9.

    Article  PubMed  CAS  Google Scholar 

  • Skoura A, Sanchez T, Claffey K, Mandala SM, Proia RL, Hla T. Essential role of sphingosine 1-phosphate receptor 2 in pathological angiogenesis of the mouse retina. J Clin Invest. 2007;117(9):2506–16.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Sohn JH, Bora PS, Jha P, Tezel TH, Kaplan HJ, Bora NS. Complement, innate immunity and ocular disease. Chem Immunol Allergy. 2007;92:105–14.

    Article  PubMed  CAS  Google Scholar 

  • Sommer A, Tielsch JM, Katz J, Quigley HA, Gottsch JD, Javitt J, Singh K. Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans: the Baltimore eye survey. Arch Ophthalmol. 1991;109(8):1090–5.

    Article  PubMed  CAS  Google Scholar 

  • Sparrow JR, Nakanishi K, Parish CA. The lipofuscin fluorophore A2E mediates blue light induced damage to retinal pigmented epithelial cells. Invest Ophthalmol Vis Sci. 2000;41:1981–9.

    PubMed  CAS  Google Scholar 

  • Stewart MW. Aflibercept (VEGF Trap-Eye) for the treatment of exudative age-related macular degeneration. Expert Rev Clin Pharmacol. 2013;6(2):103–13.

    Article  PubMed  CAS  Google Scholar 

  • Stone J, Itin A, Alon T, Pe’er J, Gnessin H, Chan-Ling T, Keshet E. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci. 1995;15:4738–47.

    PubMed  CAS  Google Scholar 

  • Su Y, Cheng J, Liu H, Wang F, Zhao S. Adenovirus conducted connective tissue growth factor on extracellular matrix in trabecular meshwork and its role on aqueous humor outflow facility. Mol Biol Rep. 2013;40(11):6091–6.

    Article  PubMed  CAS  Google Scholar 

  • Tao W. Application of encapsulated cell technology for retinal degenerative diseases. Expert Opin Biol Ther. 2006;6(7):717–26.

    Article  PubMed  CAS  Google Scholar 

  • Thurman JM, Holers VM. The central role of the alternative complement pathway in human disease. J Immunol. 2006;176(3):1305–10.

    Article  PubMed  CAS  Google Scholar 

  • Trujillo CA, Nery AA, Alves JM, Martins AH, Ulrich H. Development of the anti-VEGF aptamer to a therapeutic agent for clinical ophthalmology. Clin Ophthalmol. 2007;1(4):393–402.

    PubMed Central  PubMed  CAS  Google Scholar 

  • Tsui I, Pan CK, Rahimy E, Schwartz SD. Ocriplasmin for vitreoretinal diseases. J Biomed Biotechnol. 2012;2012:354979.

    Google Scholar 

  • Vasudevan SK, Gupta V, Crowston JG. Neuroprotection in glaucoma. Indian J Ophthalmol. 2011;59(Suppl):S102–13.

    Article  PubMed Central  PubMed  Google Scholar 

  • Wang J, Liu X, Zhong Y. Rho/Rho-associated kinase pathway in glaucoma (Review). Int J Oncol. 2013;43(5):1357–67.

    PubMed  CAS  Google Scholar 

  • Wen R, Cheng T, Li Y, Cao W, Steinberg RH. α2-adrenergic agonists induce basic fibroblast growth factor expression in photoreceptors in vivo and ameliorate light damage. J Neurosci. 1996;16:5986–92(1).

    PubMed  CAS  Google Scholar 

  • Wu WC, Drenser KA, Lai M, Capone A, Trese MT. Plasmin enzyme-assisted vitrectomy for primary and reoperated eyes with stage 5 retinopathy of prematurity. Retina. 2008;28 suppl 3:S75–80.

    Article  PubMed  Google Scholar 

  • Xie B, Shen J, Dong A, Rashid A, Stoller G, Campochiaro PA. Blockade of sphingosine-1-phosphate reduces macrophage influx and retinal and choroidal neovascularization. J Cell Physiol. 2009;218(1):192–8.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature. 2000;407:242–8.

    Article  PubMed  CAS  Google Scholar 

  • Yucel YH, Zhang Q, Weinreb RN, Kaufman PL, Gupta N. Effects of retinal ganglion cell loss on magno-, parvo-, koniocellular pathways in the lateral geniculate nucleus and visual cortex in glaucoma. Prog Retin Eye Res. 2003;22:465–81.

    Article  PubMed  Google Scholar 

  • Zehetner C, Kralinger MT, Modi YS, Waltl I, Ulmer H, Kirchmair R, Bechrakis NE, Kieselbach GF. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial. Acta Ophthalmol. 2015;93(2):e154–9.

    Article  PubMed  CAS  Google Scholar 

  • Zhang K, Hopkins JJ, Heier JS, Birch DG, Halperin LS, Albini TA, Brown DM, Jaffe GJ, Tao W, Williams GA. Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration. Proc Natl Acad Sci U S A. 2011;108(15):6241–5.

    Article  PubMed Central  PubMed  Google Scholar 

  • Zipfel PF, Skerka C, Hellwage J, Jokiranta ST, Meri S, Brade V, Kraiczy P, Noris M, Remuzzi G. Factor H family proteins: on complement, microbes and human diseases. Biochem Soc Trans. 2002;30(Pt 6):971–8.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Pharmacology, d3 Medicine, Parsippany, NJ, USA

    Rajinder K. Bhardwaj MS, PhD

Authors
  1. Rajinder K. Bhardwaj MS, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rajinder K. Bhardwaj MS, PhD .

Editor information

Editors and Affiliations

  1. Ocular Pharmacology and Pharmacy, Dr. RP Centre for Ophthalmic Sciences, New Delhi, India

    Thirumurthy Velpandian

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Bhardwaj, R.K. (2016). Opportunities for the Development of Newer Drugs for Ocular Use. In: Velpandian, T. (eds) Pharmacology of Ocular Therapeutics. Adis, Cham. https://doi.org/10.1007/978-3-319-25498-2_2

Download citation

Publish with us

Policies and ethics

Search

Navigation